CN111394311A - 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 - Google Patents
一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 Download PDFInfo
- Publication number
- CN111394311A CN111394311A CN202010310198.9A CN202010310198A CN111394311A CN 111394311 A CN111394311 A CN 111394311A CN 202010310198 A CN202010310198 A CN 202010310198A CN 111394311 A CN111394311 A CN 111394311A
- Authority
- CN
- China
- Prior art keywords
- serum
- cells
- corneal epithelial
- epithelial cells
- mesenchymal stem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002919 epithelial cell Anatomy 0.000 title claims abstract description 39
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 26
- 230000001939 inductive effect Effects 0.000 title claims abstract description 24
- 239000001963 growth medium Substances 0.000 title description 13
- 230000004069 differentiation Effects 0.000 claims abstract description 25
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims abstract description 24
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 24
- 239000002609 medium Substances 0.000 claims abstract description 22
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims abstract description 13
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims abstract description 12
- 102000003982 Parathyroid hormone Human genes 0.000 claims abstract description 12
- 108090000445 Parathyroid hormone Proteins 0.000 claims abstract description 12
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 12
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 12
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 12
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 12
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000199 parathyroid hormone Substances 0.000 claims abstract description 12
- 229960001319 parathyroid hormone Drugs 0.000 claims abstract description 12
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940016667 resveratrol Drugs 0.000 claims abstract description 12
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 12
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims abstract description 12
- 229960002930 sirolimus Drugs 0.000 claims abstract description 12
- 229960003604 testosterone Drugs 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000012679 serum free medium Substances 0.000 claims abstract description 8
- 238000001914 filtration Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 230000006698 induction Effects 0.000 description 21
- 239000010410 layer Substances 0.000 description 13
- 102000003951 Erythropoietin Human genes 0.000 description 9
- 108090000394 Erythropoietin Proteins 0.000 description 9
- 229940105423 erythropoietin Drugs 0.000 description 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 9
- 210000004087 cornea Anatomy 0.000 description 8
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 7
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 3
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000021921 corneal disease Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 206010011039 Corneal perforation Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 210000005009 osteogenic cell Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/37—Parathyroid hormone [PTH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
- C12N2501/392—Sexual steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
Abstract
本发明涉及干细胞诱导分化领域，尤其涉及一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，通过以下方法制备：每1L所述诱导分化无血清完全培养基中含有白藜芦醇5‑10μmol、淫羊藿苷2‑4μmol、阿司匹林1‑3nmol、甲状旁腺激素1‑3nmol、氢化可的松5‑10nmol、雷帕霉素1‑3mg、睾酮2‑10μg、EPO 2‑10μg、LIF 2‑10μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。本发明的一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，采用中药成分白藜芦醇、淫羊藿苷联合阿司匹林、甲状旁腺激素、氢化可的松、雷帕霉素、睾酮和生长因子，协同诱导间充质干细胞定向分化为角膜上皮细胞，所选用的诱导成分均无毒，诱导效率高，诱导时间短，诱导获得角膜上皮细胞活性好，细胞移植后无排斥，无伦理问题，安全性高。
Description
技术领域
本发明涉及干细胞诱导分化领域，尤其涉及一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基。
背景技术
角膜上皮细胞层位于角膜外表面。角膜上层细胞有5～6层，每层排列极为整齐而且紧密，最深层为单层矮柱状的基底细胞；深层上面有2～3层多边形的翼状细胞，最上面是2～3层多边形的表层细胞。表层细胞的最浅层为不角化的扁平细胞，表皮细胞之间的间隙不清晰，表层细胞膜很光滑，胞浆清晰透明，胞浆突起互相结合成桥，核仍存在。此细胞透光度极强。角膜上皮细胞抵抗力、再生能力都很强，深层细胞尚可进行有丝***。角膜上皮遭受外伤和感染后，一般均能很快恢复。
多种致病因素如眼外伤、手术创伤、炎症、药物毒性均可造成角膜缘损伤，造成角膜缘干细胞功能障碍，导致上皮细胞缺失，从而导致增加角膜感染、穿孔、新生血管化的危险。角膜移植是目前角膜盲治愈的惟一有效手段。据统计全国角膜病盲患者约有400万～500万，其中大部分通过角膜移植手术可以复明。但我国每年仅能开展约1万例角膜移植手术，主要原因是捐献的供体角膜数量严重不足，限制了手术的推广应用，致使绝大多数角膜盲患者无法通过角膜移植重见光明，因此体外重建组织工程角膜是目前解决供体角膜材料不足的重要突破口。
但是目前角膜组织工程中遇到一些瓶颈问题,如角膜上皮种子细胞的来源问题。角膜上皮的研究使人们对角膜的生理、病理特点和角膜疾病有了更深入的了解，但由于分化后的角膜上皮细胞体外生长的生命周期很短，只能传2～3代，获得的细胞数量少，花费较高，限制了角膜组织的研究和组织工程化角膜的构建。因此如何获得增殖能力强、能不断***生长的角膜上皮细胞，以补充细胞的不断更新，成为获得角膜上皮种子细胞的首要任务。通过建立角膜上皮细胞系能够长期稳定地为不同研究目的提供所需的细胞，如上皮的增殖、分化、眼科用药的测试、角膜疾病新的治疗方法的开发等。
间充质干细胞来源广泛、取材容易，便于自体移植，具有强大的增殖能力，在体外长期培养过程中可以始终保持其多向分化潜能，在特定条件诱导下可以分化为成骨、软骨、肌腱、肌细胞、脂肪细胞、神经细胞和肝细胞等，是一种理想的组织工程种子细胞。间充质干细胞已经成为干细胞研究的热点，经诱导后分化为角膜上皮细胞，可用于角膜损伤的修复。
干细胞的分化是部分基因选择性地被激活或差异性表达，从而控制细胞表型和蛋白质的特异性分布。间充质干细胞分化为特定细胞类型主要取决于基因的激活，而细胞外微环境中各种因子类型和浓度则是基因激活的重要因素。本发明的一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，采用中药成分白藜芦醇、淫羊藿苷联合阿司匹林、甲状旁腺激素、氢化可的松、雷帕霉素、睾酮和生长因子，协同诱导间充质干细胞定向分化为角膜上皮细胞，所选用的诱导成分均无毒，诱导效率高，诱导时间短，诱导获得角膜上皮细胞活性好，细胞移植后无排斥，无伦理问题，安全性高。
发明内容
本发明的目的是针对现有的诱导培养基及诱导方法存在的缺陷，提供一种诱导效率高，诱导步骤少，诱导时间短，诱导获得角膜上皮细胞活性好，细胞移植后无排斥，无伦理问题，安全性高的诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基。
为实现上述目的，本发明采用的技术方案是：一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，通过以下方法制备：每1L所述诱导分化无血清完全培养基中含有白藜芦醇5-10μmol、淫羊藿苷2-4μmol、阿司匹林1-3nmol、甲状旁腺激素1-3nmol、氢化可的松5-10nmol、雷帕霉素1-3mg、睾酮2-10μg、EPO 2-10μg、LIF 2-10μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
优选的，一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，通过以下方法制备：每1L所述诱导分化无血清完全培养基中含有白藜芦醇8μmol、淫羊藿苷3μmol、阿司匹林2nmol、甲状旁腺激素2nmol、氢化可的松7nmol、雷帕霉素2mg、睾酮7μg、EPO 7μg、LIF 7μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
本发明的一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，具有以下优势：1、无需基因转染，故无基因改变和癌症风险；2、诱导步骤少；3、诱导时间短；4、5、诱导分化效率高；5、本发明的诱导剂，各成分均安全无毒性；6、间充质干细胞诱导分化为角膜上皮细胞后，移植后无排斥，无伦理问题，安全性高，具有广阔的临床应用前景。
附图说明
图1 本发明培养基诱导间充质干细胞分化后出现角膜上皮细胞的形态（×400）。
具体实施方式
下述实施例中的实验方法，如无特别说明，均为常规方法。实验所用器具仪器试剂皆可通过商业途径获得。
实施例1 本发明的一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基各成分均为市售产品：白藜芦醇，品牌Sigma，货号R5010；淫羊藿苷，品牌上海微晶生物, 货号489-32-7；阿司匹林，品牌Sigma，货号A2093-100G；甲状旁腺激素，品牌Sigma, 货号P7036；氢化可的松，品牌Sigma,货号H3160；雷帕霉素，品牌TargetMol，货号T1537，睾酮，品牌Sigma, 货号T1500；EPO（***），品牌PeproTech ，货号CYT-201；LIF（白血病抑制因子），品牌PeproTech，货号96-300-05-5；角膜上皮细胞无血清培养基（CEpiCM），品牌ScienCell，货号6511。
一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，由以下组分，分别按以下浓度配比而成：每1L所述诱导分化无血清完全培养基中含有白藜芦醇8μmol、淫羊藿苷3μmol、阿司匹林2nmol、甲状旁腺激素2nmol、氢化可的松7nmol、雷帕霉素2mg、睾酮7μg、EPO 7μg、LIF 7μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
实施例2 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，由以下组分，分别按以下浓度配比而成：每1L所述诱导分化无血清完全培养基中含有白藜芦醇5μmol、淫羊藿苷2μmol、阿司匹林1nmol、甲状旁腺激素1nmol、氢化可的松5nmol、雷帕霉素1mg、睾酮2μg、EPO 2μg、LIF 2μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
实施例3一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，由以下组分，分别按以下浓度配比而成：每1L所述诱导分化无血清完全培养基中含有白藜芦醇10μmol、淫羊藿苷4μmol、阿司匹林3nmol、甲状旁腺激素3nmol、氢化可的松10nmol、雷帕霉素3mg、睾酮10μg、EPO 10μg、LIF 10μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
实施例4以人脂肪间充质干细胞为例，采用实施例1制备的诱导培养基，对间充质干细胞进行角膜上皮细胞诱导分化实验，步骤如下：
诱导脂肪间充质干细胞分化为角膜上皮细胞：传3代的MSC，接种于事先放置有经多聚赖氨酸处理的消毒盖玻片的6孔板，制备细胞爬片。待细胞接近80%融合，生长旺盛时再进行诱导分化。实验分组如表1：
表1 实验分组
| 组别 | 诱导条件 |
| 本发明诱导组 | 本发明的诱导培养基，诱导5d。 |
| 条件培养基组 | 条件培养基制备：人角膜缘干细胞用含20%FBS+10μg/LEGF的DMEM/F12培养基，置37°C的5%二氧化碳培养箱，每2d更换培养基一次。收集每次更换的培养基，移入离心管，1000rpm/min离心5分钟，收集上清于无菌管中，置于-20°C冰箱备用。用上述条件培养基诱导30d。 |
| 共培养组 | 按Millipore公司说明， 用Transwell共培养体系。将人角膜缘干细胞接种到Transwell小室，再放入到6孔板，与间充质干细胞共同培养诱导7d。 |
诱导后细胞进行鉴定：选择CK3、CK12、CK19作为角膜上皮细胞标记物，免疫细胞化学法检测诱导前后CK3、CK12、CK19的表达情况，随机抽取4张玻片，200倍视野下随机选取5个视野，分别计算阳性细胞的比例。阳性细胞占总细胞比例以均数±标准差（
）表示。采用SPSS11.0软件进行统计分析，实验数据以（
）表示，多组比较采用方差分析，两组间率的比较采用χ2检验，P<0.05认为有统计学意义。三组诱导结果如表2所示：
表2 三组诱导结果（n=20，
）
如表2所示，本发明诱导组诱导分化后CK3、CK12、CK19阳性细胞率高于条件培养基组和共培养组（P<0.05），说明本发明培养基诱导效率明显高于条件培养基组和共培养组，达到了90%以上。
综上，本发明的一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基诱导效率最高，诱导时间最短，值得推广。
Claims (2)
1.一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，其特征是通过以下方法制备：每1L所述诱导分化无血清完全培养基中含有白藜芦醇5-10μmol、淫羊藿苷2-4μmol、阿司匹林1-3nmol、甲状旁腺激素1-3nmol、氢化可的松5-10nmol、雷帕霉素1-3mg、睾酮2-10μg、EPO 2-10μg、LIF 2-10μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
2.根据权利要求1所述的一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基，其特征是通过以下方法制备：每1L所述诱导分化无血清完全培养基中含有白藜芦醇8μmol、淫羊藿苷3μmol、阿司匹林2nmol、甲状旁腺激素2nmol、氢化可的松7nmol、雷帕霉素2mg、睾酮7μg、EPO 7μg、LIF 7μg，余量为角膜上皮细胞无血清培养基，混匀后过滤除菌即可。
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010310198.9A CN111394311B (zh) | 2020-04-20 | 2020-04-20 | 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 |
| EP20873344.4A EP4141109A1 (en) | 2020-04-20 | 2020-05-25 | Serum-free complete culture medium capable of inducing differentiation of mesenchymal stem cells from corneal epithelial cells |
| US17/283,491 US20220041982A1 (en) | 2020-04-20 | 2020-05-25 | A serum-free complete medium for inducing differentiation of a mesenchymal stem cell to a corneal epithelial cell |
| PCT/CN2020/092071 WO2021212592A1 (zh) | 2020-04-20 | 2020-05-25 | 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 |
| KR1020217008536A KR102552191B1 (ko) | 2020-04-20 | 2020-05-25 | 중간엽 줄기세포가 각막 상피세포로의 분화를 유도하는 무혈청 완전 배지 |
| JP2021516585A JP7239686B2 (ja) | 2020-04-20 | 2020-05-25 | 角膜上皮細胞への間葉系幹細胞の分化を誘導する無血清完全培地 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010310198.9A CN111394311B (zh) | 2020-04-20 | 2020-04-20 | 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111394311A true CN111394311A (zh) | 2020-07-10 |
| CN111394311B CN111394311B (zh) | 2022-07-01 |
Family
ID=71437025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010310198.9A Active CN111394311B (zh) | 2020-04-20 | 2020-04-20 | 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220041982A1 (zh) |
| EP (1) | EP4141109A1 (zh) |
| JP (1) | JP7239686B2 (zh) |
| KR (1) | KR102552191B1 (zh) |
| CN (1) | CN111394311B (zh) |
| WO (1) | WO2021212592A1 (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2010134619A1 (ja) * | 2009-05-18 | 2012-11-12 | 国立大学法人東北大学 | 人工多能性幹細胞からの上皮系前駆細胞・幹細胞群及び角膜上皮細胞群の分化誘導方法 |
| US20130251692A1 (en) * | 2010-12-02 | 2013-09-26 | Institut National De La Sante Et De La Recherche Medicale | Methods of generating corneal cells and cell populations comprising same |
| CN105062970A (zh) * | 2015-08-25 | 2015-11-18 | 北京瑞思德生物医学研究院 | 一种将间充质干细胞诱导成神经细胞的诱导剂及诱导分化完全培养基 |
| CN105087466A (zh) * | 2015-08-28 | 2015-11-25 | 广州赛莱拉干细胞科技股份有限公司 | 诱导脐带间充质干细胞向角膜上皮细胞分化的培养基和方法 |
| CN105176912A (zh) * | 2015-08-28 | 2015-12-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种培养基及其应用、制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60326002D1 (de) * | 2002-10-22 | 2009-03-12 | Waratah Pharmaceuticals Inc | Behandlung von diabetes. |
| BRPI0514387B8 (pt) | 2004-08-16 | 2021-05-25 | Cellresearch Corp Pte Ltd | método para isolar células-tronco epiteliais ou mesenquimais/progenitoras da membrana amniótica do cordão umbilical, método in vitro para cultivar células-tronco mesenquimais/progenitoras, composição farmacêutica e uso de uma célula-tronco epitelial ou mesenquimal/progenitora |
| WO2008129563A2 (en) * | 2007-04-23 | 2008-10-30 | Stempeutics Research Private Limited, | Human mesenchymal stem cells and preparation thereof |
| CN107574142B (zh) * | 2007-11-27 | 2021-07-06 | 生命扫描有限公司 | 人胚胎干细胞的分化 |
| CN103184190A (zh) | 2013-04-11 | 2013-07-03 | 陈云燕 | 一种将脂肪干细胞转化为睾酮分泌细胞的诱导剂及培养基 |
| JP2015019628A (ja) | 2013-07-19 | 2015-02-02 | 学校法人慶應義塾 | 単層細胞層の製造方法 |
| KR101690872B1 (ko) * | 2014-08-19 | 2016-12-29 | 이화여자대학교 산학협력단 | 편도 유래 중간엽 줄기세포로부터 인슐린 분비 세포의 분화 방법 |
| EP3246394B1 (en) | 2015-01-15 | 2022-11-23 | Osaka University | Method for inducing differentiation of corneal epithelial cells from pluripotent stem cells |
| CN104845932A (zh) * | 2015-04-29 | 2015-08-19 | 天津中医药大学 | 淫羊藿苷的新用途 |
| CN105132369B (zh) * | 2015-08-25 | 2018-06-26 | 青岛瑞思科生物科技有限公司 | 一种将间充质干细胞转化为睾酮分泌细胞的诱导剂及诱导培养基 |
| CN105085938B (zh) | 2015-08-28 | 2018-03-27 | 广州赛莱拉干细胞科技股份有限公司 | 白芨多糖水凝胶、培养基质及其应用与诱导脐带间充质干细胞向角膜上皮细胞分化的方法 |
-
2020
- 2020-04-20 CN CN202010310198.9A patent/CN111394311B/zh active Active
- 2020-05-25 KR KR1020217008536A patent/KR102552191B1/ko active IP Right Grant
- 2020-05-25 EP EP20873344.4A patent/EP4141109A1/en active Pending
- 2020-05-25 JP JP2021516585A patent/JP7239686B2/ja active Active
- 2020-05-25 WO PCT/CN2020/092071 patent/WO2021212592A1/zh unknown
- 2020-05-25 US US17/283,491 patent/US20220041982A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2010134619A1 (ja) * | 2009-05-18 | 2012-11-12 | 国立大学法人東北大学 | 人工多能性幹細胞からの上皮系前駆細胞・幹細胞群及び角膜上皮細胞群の分化誘導方法 |
| US20130251692A1 (en) * | 2010-12-02 | 2013-09-26 | Institut National De La Sante Et De La Recherche Medicale | Methods of generating corneal cells and cell populations comprising same |
| CN105062970A (zh) * | 2015-08-25 | 2015-11-18 | 北京瑞思德生物医学研究院 | 一种将间充质干细胞诱导成神经细胞的诱导剂及诱导分化完全培养基 |
| CN105087466A (zh) * | 2015-08-28 | 2015-11-25 | 广州赛莱拉干细胞科技股份有限公司 | 诱导脐带间充质干细胞向角膜上皮细胞分化的培养基和方法 |
| CN105176912A (zh) * | 2015-08-28 | 2015-12-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种培养基及其应用、制备方法 |
Non-Patent Citations (3)
| Title |
|---|
| KATIKIREDDY, KR等: "Differentiation Potential of Limbal Fibroblasts and Bone Marrow Mesenchymal Stem Cells to Corneal Epithelial Cells", 《STEM CELLS》 * |
| 王宇静等: "人角膜上皮细胞体外培养的研究进展", 《眼科新进展》 * |
| 黄小勇等: "无血清培养的角膜缘干细胞的生物学特性", 《第三军医大学学报》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220041982A1 (en) | 2022-02-10 |
| KR20210131302A (ko) | 2021-11-02 |
| EP4141109A1 (en) | 2023-03-01 |
| JP7239686B2 (ja) | 2023-03-14 |
| WO2021212592A1 (zh) | 2021-10-28 |
| JP2022534332A (ja) | 2022-07-29 |
| CN111394311B (zh) | 2022-07-01 |
| KR102552191B1 (ko) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104450611B (zh) | 一种人羊膜间充质干细胞原代分离及培养方法 | |
| CN106167790B (zh) | 人胚胎干细胞定向诱导分化为角膜内皮细胞的方法 | |
| US20200239842A1 (en) | Preparation and Expansion Methods for Human Pluripotent Stem Cell-Derived Human Retinal Pigment Epithelial Cells | |
| US20190264179A1 (en) | Serum-free medium inducing differentiation of umbilical cord mesenchymal stem cell into insulin-secretion-like cell and preparation method and use thereof | |
| CN103881973A (zh) | 一种用于诱导分化间充质干细胞的培养基及其方法 | |
| CN102899285A (zh) | 一种体外诱导胚胎干细胞分化成为神经细胞方法 | |
| CN106244548A (zh) | 木犀草素在诱导间充质干细胞向神经细胞定向分化中的用途 | |
| RU2409663C1 (ru) | Способ получения дедифференцированных клеток ретинального пигментного эпителия глаза взрослого человека | |
| CN102604886A (zh) | 使人的体细胞逆向分化产生自体视网膜干细胞和自体视网膜细胞的方法、试剂盒及用途 | |
| CN111088229B (zh) | 一种人多能干细胞来源的视网膜前体细胞的制备方法 | |
| CN111110921A (zh) | 一种组织工程后板层角膜的体外构建方法 | |
| CN111394311B (zh) | 一种诱导间充质干细胞向角膜上皮细胞分化的无血清完全培养基 | |
| US20090047738A1 (en) | Feeder cell derived from tissue stem cell | |
| CN106939299A (zh) | microRNA重编程体细胞为神经干细胞的制备方法及应用 | |
| WO2022148500A2 (zh) | 多聚嘧啶序列结合蛋白在制备脊髓损伤的修复药物中的应用 | |
| CN105087466A (zh) | 诱导脐带间充质干细胞向角膜上皮细胞分化的培养基和方法 | |
| WO2018155952A2 (ko) | 인간 뇌 조직 유래 신경줄기세포의 고효율 분리 방법 | |
| CN112569227B (zh) | 一种具有神经保护功能的3d立体移植材料体系及其应用 | |
| CN107304412A (zh) | 视网膜色素上皮细胞的培养基及其应用 | |
| CN106834211B (zh) | 汗腺细胞的培养基及其制备方法 | |
| CN112126627B (zh) | 一种犬角膜上皮细胞永生化细胞系的构建方法和应用 | |
| EP4331595A1 (en) | Use of retinal pigment epithelial cells in replacement of corneal endothelia | |
| CN106244550A (zh) | 一种细胞培养液及其应用和诱导骨骼肌干细胞向神经样细胞分化的方法 | |
| CN115141803A (zh) | 使用人多潜能干细胞诱导获得脊髓谷氨酸能中间神经元的方法及其应用 | |
| CN117143819A (zh) | 一种神经细胞的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A serum-free complete culture medium for inducing mesenchymal stem cells to differentiate into corneal epithelial cells Effective date of registration: 20230329 Granted publication date: 20220701 Pledgee: Qingdao Huitong Chinese financing Company limited by guarantee Pledgor: QINGDAO RESTORE BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023370010033 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20220701 Pledgee: Qingdao Huitong Chinese financing Company limited by guarantee Pledgor: QINGDAO RESTORE BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023370010033 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |